01—Abstract
Summary
Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Zoetis (NYSE: ZTS) reported third quarter 2025 results on November 4, 2025, showing modest top-line growth that was offset by a meaningful reduction in full-year revenue guidance.
Reported revenue was $2.4 billiona, up 1% year over year, with organic operational growth of 4%. Reported net income attributable to Zoetis was $721 million, or $1.63 per diluted share, up 6% and 9% respectively. Adjusted net income was $754 million, or $1.70 per diluted share, up 9% on an organic operational basis.
Growth in the U.S. segment was driven by parasiticides, diagnostics and dermatology, offset by declines in the osteoarthritis monoclonal antibodies (Librela and Solensia) and the divestiture of the medicated feed additive portfolio. International revenue grew 6%b organically, led by companion animal products. The key investor takeaway is the guidance revision.
Management lowered full-year 2025 revenue guidance to $9.400c–$9.475 billion, with organic operational growth of 5.5%–6.5%, down from $9.450–$9.600 billion and 6.5%–8% previously, citing broader macro trends and the operating environment in the back half of the year. Organic operational adjusted net income growth was narrowed to 5.5%–7.0% from 5.5%–7.5%. Adjusted diluted EPS guidance was maintained at $6.30–$6.40, supported by cost discipline, with adjusted SG&A guidance reduced and the adjusted cost of sales ratio guided to approximately 28.3% of revenue.
Management also highlighted regulatory progress, including Lenivia (a long-acting OA pain mAb for dogs) approved in Canada with EU marketing authorization expected in Q4 2025, Portela approved in the EU for cats, and a conditional FDA approval for Dectomax-CA1 against New World screwworm. Management plans an Innovation webcast on December 2, 2025. The filing states that management expects a significant approval in a major market each year for the next several years.
02—Key points
Key Highlights
- Q3 2025 revenue of $2.4 billion, up 1% reported and up 4% on an organic operational basis; U.S. revenue fell 2% reported (up 3% organically) while International rose 3% reported (up 6% organically).
- GAAP diluted EPS of $1.63 (up 9%) and adjusted diluted EPS of $1.70 (up 12% organically); adjusted net income of $754 million excludes $33 million of purchase accounting, acquisition/divestiture, and significant items.
- Full-year 2025 revenue guidance cut to $9.400–$9.475 billion from $9.450–$9.600 billion; organic operational growth lowered to 5.5%–6.5% from 6.5%–8%.
- Adjusted net income organic growth guidance narrowed to 5.5%–7.0% (from 5.5%–7.5%); adjusted diluted EPS guidance maintained at $6.30–$6.40 and reported EPS at $5.90–$6.00.
- Osteoarthritis monoclonal antibody franchise (Librela and Solensia) declined, offsetting growth in parasiticides (Simparica, Revolution), diagnostics, and dermatology (Apoquel Chewable).
- U.S. livestock sales fell 9% reported, largely due to the medicated feed additive divestiture, though organic livestock sales rose 14% on cattle and vaccine strength.
- Pipeline milestones include Lenivia approval in Canada and expected EU authorization in Q4 2025, Portela EU approval for feline OA pain, and a conditional FDA approval for Dectomax-CA1 against New World screwworm.
03—Questions
Frequently Asked Questions
Why did Zoetis lower its full-year 2025 revenue guidance?
Management attributed the revision to broader macro trends and the operating environment in the back half of 2025, along with its continued disciplined approach to cost management and investment. The revenue range was reduced by $150 million at the midpoint-low end and $125 million at the top end, and organic operational growth was reduced from 6.5%–8% to 5.5%–6.5%. The filing also notes that guidance reflects foreign exchange rates from late October and assumptions about announced tariffs.
Did Zoetis change its EPS outlook?
Adjusted diluted EPS guidance was maintained at $6.30–$6.40, and reported diluted EPS guidance was unchanged at $5.90–$6.00. Reported net income guidance was $2.625–$2.665 billion and adjusted net income guidance was $2.800–$2.840 billion, with the adjusted net income organic growth range narrowed to 5.5%–7.0%.
What drove the difference between GAAP and adjusted results in Q3 2025?
The $33 million pre-tax gap between GAAP and adjusted income in Q3 2025 consisted mainly of $32 million in purchase accounting adjustments, primarily amortization of acquired intangibles, plus $7 million in certain significant items, including business process transformation costs ($8 million), partially offset by other items. Acquisition and divestiture-related costs were nil in the quarter. Management guides to approximately $75 million of significant items and acquisition/divestiture costs for full-year 2025.
What is the outlook for the osteoarthritis pain franchise?
The filing shows Librela and Solensia declines were a drag on U.S. companion animal sales in Q3 2025. Management is pinning growth on new products, including Lenivia, a long-acting monoclonal antibody that is approved in Canada with a Canadian launch planned for 2026 and EU authorization expected in Q4 2025, and Portela, which is approved in the EU for feline OA pain with EU launch expected in 2026. Management also plans an Innovation webcast on December 2, 2025 to provide pipeline updates.
What is the impact of the U.S. commercial reorganization?
Zoetis is realigning its U.S. field structure to create a simpler, more agile commercial organization, aiming to expand reach, deepen customer relationships, and extend the lifecycle of key franchises. The filing does not quantify the financial impact or associated costs of this restructuring, so investors should watch for details on the December innovation webcast or subsequent filings.
04—Continue